MedTrace Logo

Topical Mebo Versus Lidocane in Healing Time of Traumatic Oral Ulcer

NCT06184282 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2024-01-03

No results posted yet for this study

Summary

This study aims to assess topical MEBO application on pain relief and wound healing.

Conditions

  • Mebo
  • Lidocaine
  • Healing
  • Traumatic Oral Ulceration

Interventions

DRUG

MEBO

MEBO (Julphar®, Ras Al Khaimah, United Arab Emirates) was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.

DRUG

Lidocaine

Lidocaine gel was applied using sterile plastic brush daily and the patients were recalled at 2, 5 and 10 days for evaluating the healing of the ulcer.

Sponsors & Collaborators

  • October 6 University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2023-08-01
Completion
2023-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06184282 on ClinicalTrials.gov